Analysis compares semaglutide safety with bariatric surgery for weight management, evaluating whether the drug is a safer alternative for obese patients.
Key findingAnalysis compares semaglutide safety with bariatric surgery for weight management, evaluating whethe
What the researchers found
Analysis compares semaglutide safety with bariatric surgery for weight management, evaluating whether the drug is a safer alternative for obese patients.
Why it matters
Relevant to peptide-based therapeutic applications.
The numbers in context
Retrospective review of THAs from 2012-2024 comparing semaglutide users versus prior bariatric surgery patients.
How the study worked
Methodology in publication.
Who was studied
Patients undergoing total hip arthroplasty who used semaglutide or had prior bariatric surgery
What this study cannot tell us
Limitations in publication.
How to read the evidence
Based on study design.
When this study was published
Published in 2025.
The bigger picture
Contributes to peptide therapeutic evidence.
Questions still open
- Long-term implications?
- Comparison to evidence?
- Next research?
Common questions
What does this mean?
How reliable?
Read the original research
Is Semaglutide a Safer Weight-Management Option Than Bariatric Surgery for Patients Undergoing Total Hip Arthroplasty (THA)?
The Journal of arthroplasty
Citation
Alpert, Zoe; Katzman, Jonathan L; Lajam, Claudette M; Schwarzkopf, Ran; Rozell, Joshua C. (2025). Is Semaglutide a Safer Weight-Management Option Than Bariatric Surgery for Patients Undergoing Total Hip Arthroplasty (THA)?. The Journal of arthroplasty. https://doi.org/10.1016/j.arth.2025.08.068